Top

Published in:

01-10-2020 | Vaccination

Influence of provider recommendations to restart vaccines after childhood cancer on caregiver intention to vaccinate

Authors: Echo L. Warner, Perla L. Vaca Lopez, Deanna Kepka, Karely Mann, Heydon K. Kaddas, Douglas Fair, Mark Fluchel, Elizabeth D. Knackstedt, Samantha T. Pannier, Laura Martel, Anne C. Kirchhoff

Published in: Journal of Cancer Survivorship | Issue 5/2020

Abstract

Purpose

We studied the influence of oncology and primary care provider (PCP) recommendations on caregiver intentions to restart vaccines (e.g., catch-up or boosters) after cancer treatment.

Methods

We surveyed primary caregivers ages 18 or older with a child who had completed cancer treatment 3–36 months prior (N = 145) about demographics, child’s vaccination status, and healthcare factors (e.g., provider recommendations, barriers, preferences for vaccination). We compared these factors by caregiver’s intention to restart vaccines (“vaccine intention” vs. “no intent to vaccinate”) using bivariate and multivariable analyses.

Results

Caregivers were primarily ages 30–39 years (54.9%), mothers (80.6%), college graduates (44.4%), non-Hispanic (89.2%), and married (88.2%). Overall, 34.5% of caregivers did not know which vaccines their child needed. However, 65.5% of caregivers reported vaccine intention. Fewer caregivers with no intention to vaccinate believed that vaccinating their child helps protect others (85.4 vs. 99.0%, p < 0.01), that vaccines are needed when diseases are rare (83.7 vs. 100.0%, p < 0.01), and that vaccines are safe (80.4 vs. 92.6%, p = 0.03) and effective (91.5 vs. 98.9%, p = 0.04) compared with vaccine intention caregivers, respectively. Provider recommendations increased caregivers’ likelihood of vaccine intention (oncologist RR = 1.65, 95% CI 1.27–2.12, p < 0.01; PCP RR = 1.51, 95% CI 1.19–1.94, p < 0.01).

Conclusions

Provider recommendations positively influence caregivers’ intention to restart vaccines after childhood cancer. Guidelines are needed to support providers in making tailored vaccine recommendations.

Implications for Cancer Survivors

Timely vaccination after childhood cancer protects patients against vaccine-preventable diseases during survivorship. Caregivers may benefit from discussing restarting vaccinations after cancer with healthcare providers.

Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2018. Centers for Disease Control and Prevention. 2018. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html. Accessed 10/25/2018.

Children’s Oncology Group. Long-term follow-up guidelines: for survivors of childhood, adolescent, and young adult cancers. In: Group CsO, editor. Version 4.0 ed2013.

Long-term follow-up care for pediatric cancer survivors. Pediatrics. 2009;123(3):906-15. doi:10.1542/peds.2008-3688.

Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–18. https://doi.org/10.1093/cid/cit816.CrossRefPubMed

Han JH, Harmoney KM, Dokmeci E, Torrez J, Chavez CM, Cordova de Ortega L, et al. Dynamic re-immunization of off-treatment childhood cancer survivors: an implementation feasibility study. PloS One. 2018;13(2):e0191804. https://doi.org/10.1371/journal.pone.0191804.CrossRefPubMedPubMedCentral

Fayea NY, Fouda AE, Kandil SM. Immunization status in childhood cancer survivors: a hidden risk which could be prevented. Pediatr Neonatol. 2017;58(6):541–5. https://doi.org/10.1016/j.pedneo.2016.04.003.CrossRefPubMed

Patel SR, Ortin M, Cohen BJ, Borrow R, Irving D, Sheldon J, et al. Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis. 2007;44(5):635–42. https://doi.org/10.1086/511636.CrossRefPubMed

Gamble HL, Klosky JL, Parra GR, Randolph ME. Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol. 2010;35(7):704–15. https://doi.org/10.1093/jpepsy/jsp108.CrossRefPubMed

Bhatia S, Meadows AT. Long-term follow-up of childhood cancer survivors: future directions for clinical care and research. Pediatr Blood Cancer. 2006;46(2):143–8. https://doi.org/10.1002/pbc.20613.CrossRefPubMed

10.

Ojha RP, Offutt-Powell TN, Gurney JG. Influenza vaccination coverage among adult survivors of pediatric cancer. Am J Prev Med. 2014;46(6):552–8. https://doi.org/10.1016/j.amepre.2014.01.007.CrossRefPubMed

11.

Klosky JL, Favaro B, Peck KR, Simmons JL, Russell KM, Green DM, et al. Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer. J Cancer Surviv. 2016;10(3):449–56. https://doi.org/10.1007/s11764-015-0495-2.CrossRefPubMed

12.

Klosky JL, Russell KM, Simmons JL, Foster RH, Peck K, Green DM, et al. Medical and sociodemographic factors associated with human papillomavirus (HPV) vaccination adherence among female survivors of childhood cancer. Pediatr Blood Cancer. 2015;62(9):1630–6. https://doi.org/10.1002/pbc.25539.CrossRefPubMedPubMedCentral

13.

Castellino SM, Allen KE, Pleasant K, Keyes G, Poehling KA, Tooze JA. Suboptimal uptake of human papillomavirus (HPV) vaccine in survivors of childhood and adolescent and young adult (AYA) cancer. J Cancer Surviv. 2019;13(5):730–8. https://doi.org/10.1007/s11764-019-00791-9.CrossRefPubMed

14.

Viruses that can lead to cancer. American Cancer Society. 2016. https://www.cancer.org/cancer/cancer-causes/infectious-agents/infections-that-can-lead-to-cancer/viruses.html. Accessed 11/1/2018.

15.

Kahn KE, Santibanez TA, Zhai Y, Bridges CB. Association between provider recommendation and influenza vaccination status among children. Vaccine. 2018;36(24):3486–97. https://doi.org/10.1016/j.vaccine.2018.04.077.CrossRefPubMedPubMedCentral

16.

Lu PJ, Srivastav A, Amaya A, Dever JA, Roycroft J, Kurtz MS, et al. Association of provider recommendation and offer and influenza vaccination among adults aged >/=18years - United States. Vaccine. 2018;36(6):890–8. https://doi.org/10.1016/j.vaccine.2017.12.016.CrossRefPubMed

17.

Kirchhoff AC, Mann K, Warner EL, Kaddas HK, Fair D, Fluchel M, et al. HPV vaccination knowledge, intentions, and practices among caregivers of childhood cancer survivors. Hum Vaccin Immunother. 2019;15:1–9. https://doi.org/10.1080/21645515.2019.1619407.CrossRef

18.

Rural-Urban Commuting Area Codes. United States Department of Agriculture Economic Research Service. 2016. https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/. Accessed 11/1/2018.

19.

Marshall S, Fleming A, Moore AC, Sahm LJ. Views of parents regarding human papillomavirus vaccination: a systematic review and meta-ethnographic synthesis of qualitative literature. Res Social Adm Pharm. 2019;15(4):331–7. https://doi.org/10.1016/j.sapharm.2018.05.013.CrossRefPubMed

20.

Freed GL, Clark SJ, Butchart AT, Singer DC, Davis MM. Parental vaccine safety concerns in 2009. Pediatrics. 2010;125(4):654–9.CrossRef

21.

Vaccine safety resources for healthcare providers. Centers for Disease Control and Prevention. 2019. https://www.cdc.gov/vaccinesafety/hcproviders/hcresources.html. Accessed 05/10/2019.

22.

Healthcare professionals/providers home: patient education. Centers for Disease Control and Prevention. 2016. https://www.cdc.gov/vaccines/hcp/patient-ed/index.html. Accessed 05/10/2019.

23.

Immunizaitons. American Academy of Pediatrics. 2019. https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/immunizations/Pages/Immunizations-home.aspx. Accessed 5/10/2019.

24.

Vaccine recommendations and guidelines of the ACIP: altered immunocompetence. National Center for Immunization and Respiratory Diseases. 2017. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html. Accessed 07/16/2019.

25.

Tonorezos ES, Barnea D, Cohn RJ, Cypriano MS, Fresneau BC, Haupt R, et al. Models of care for survivors of childhood cancer from across the globe: advancing survivorship care in the next decade. J Clin Oncol. 2018;36(21):2223–30.CrossRef

26.

Mouw MS, Wertman EA, Barrington C, Earp JAL. Care transitions in childhood cancer survivorship: providers’ perspectives. J Adolesc Young Adult Oncol. 2017;6(1):111–9.CrossRef

27.

Institute of Medicine. From cancer patient to cancer survivor: lost in transition. Washington, DC: The National Academies Press; 2006.

28.

Seehusen DA, Baird D, Bode D. Primary care of adult survivors of childhood cancer. Am Fam Physician. 2010;81(10):1250–5.PubMed

29.

Ramsay JM, Mann K, Kaul S, Zamora ER, Smits-Seemann RR, Kirchhoff AC. Follow-up care provider preferences of adolescent and young adult cancer survivors. J Adolesc Young Adult Oncol. 2018;7(2):204–9. https://doi.org/10.1089/jayao.2017.0083.CrossRefPubMedPubMedCentral

30.

Warner EL, Montenegro RE, Stroup A, Kinney AY, Kirchhoff AC. Health care concerns of rural childhood cancer survivors. J Health Care Poor Underserved. 2014;25(2):901–12. https://doi.org/10.1353/hpu.2014.0095.CrossRefPubMed

31.

Oeffinger KC, Mertens AC, Hudson MM, Gurney JG, Casillas J, Chen H, et al. Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med. 2004;2(1):61–70. https://doi.org/10.1370/afm.26.CrossRefPubMedPubMedCentral

32.

Kirchhoff AC, Mann K, Warner EL, Kaddas HK, Fair D, Fluchel M, et al. HPV vaccination knowledge, intentions, and practices among caregivers of childhood cancer survivors. Hum Vacc Immunother. 2019;15(7-8):1767–75. https://doi.org/10.1080/21645515.2019.1619407.CrossRef

Title: Influence of provider recommendations to restart vaccines after childhood cancer on caregiver intention to vaccinate
Authors: Echo L. Warner
Perla L. Vaca Lopez
Deanna Kepka
Karely Mann
Heydon K. Kaddas
Douglas Fair
Mark Fluchel
Elizabeth D. Knackstedt
Samantha T. Pannier
Laura Martel
Anne C. Kirchhoff
Publication date: 01-10-2020
Publisher: Springer US
Keywords: Vaccination
Care
Published in: Journal of Cancer Survivorship / Issue 5/2020
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-020-00890-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Please log in to get access to this content

Other articles of this Issue 5/2020

The experience of outdoor physical activity for skin cancer survivors: understanding the importance of the built and natural environments

Anxiety and depression after diagnosis of high-risk primary cutaneous melanoma: a 4-year longitudinal study

Healthcare services and medication use among cancer survivors and their partners: a cross-sectional analysis of 16 European countries

Unmet expectations in prostate cancer patients and their association with decision regret

Quality of life and the negative impact of comorbidities in long-term colorectal cancer survivors: a population-based comparison

The Dutch LATER physical outcomes set for self-reported data in survivors of childhood cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer